Terminal galactose-containing cell-surface glycans

Terminal galactose-containing cell-surface glycans are complex carbohydrate structures located on the exterior of cell membranes, characterized by a galactose residue at the non-reducing end of the glycan chain. These molecules are essential for various biological processes, including cell-cell recognition, adhesion, and the regulation of immune responses through interactions with endogenous lectins like galectins. In healthy states, terminal galactose is often capped by sialic acid; however, in many diseases, particularly cancer, aberrant glycosylation leads to the exposure of these terminal residues, such as the Thomsen-Friedenreich (TF) antigen, which promotes tumor invasion and metastasis. These glycans also serve as critical attachment points for pathogens and potent toxins, such as the Ricin B chain, which exploits them for cellular entry. From a therapeutic perspective, they are targeted for selective drug delivery and toxin-mediated cell killing, and their varying levels on proteins like IgG serve as important biomarkers for inflammation, aging, and metabolic disorders.

Other names

Galactose-terminated glycansGal-terminated glycansAsialo-glycansTerminal galactosyl residuesGalactose-containing cell-surface glycoconjugates

Drugs or toxins interact with these glycans by binding to the terminal galactose residues, which can trigger receptor-mediated endocytosis (as seen with Ricin), facilitate pathogen attachment (e.g., AAV9), or mediate immune effector functions like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) when targeted by specific antibodies.